Bristol-Myers Squibb is now taking Serzone (nefazodone) off the market

Bristol-Myers Squibb is now taking Serzone (nefazodone) off the market in the U.S.

It's already off the market in Europe and Canada.

The company is not saying...but liver toxicity seems to be a likely reason. FDA added a black box warning 2 years ago.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote